← Grant listing · GrantsDue Pro

Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

National Institutes of Health · RFA-CA-27-005 · Deadline: October 1, 2026 · Advertised ceiling: $700k

Program-level history — this opportunity doesn't publish per-opportunity awards, so these numbers describe its parent program (CFDA 93.394, Cancer Detection and Diagnosis Research), not this competition alone. Labeled that way on purpose.

Listing summary

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams wil…

Eligibility: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations (other), Nonprofits with 501(c)(3), other than higher education, Nonprofits without 501(c)(3), Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others · Categories: Health · official listing ↗

Sources: NIH RePORTER (opportunity-exact) and USAspending (program-level), labeled per section. GrantsDue computes summaries only; verify anything critical against the originals. Methodology.